Activated T cell (ATC) armed with a novel anti-CD3 × anti-B7H3 bispecific antibody was found to significantly inhibit lung cancer growth in vivo compared with unarmed ATC (89), indicating that targeting B7H3 represent a novel alternative to improve current cancer therapy. This evidence concerns the gene CD276 and lung cancer.